NCT03150420终止3 期
A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 29
- 试验地点
- 20
- 主要终点
- Number of patients with 30% improvement in pain severity
研究概览
简要总结
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of acute calciphylaxis-associated pain in chronic hemodialysis patients.
详细描述
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Thiosulfate Injection for treatment of acute calciphylaxis-associated pain in chronic hemodialysis patients. Acute calciphylaxis- associated pain intensity will be the primary outcome measure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed of the investigational nature of the study and sign written informed consent
- •Willing and able to adhere to all study-related procedures, including adherence to study medication regimen
- •Male or female ≥18 years old
- •End-stage renal disease on chronic hemodialysis
- •Calciphylaxis with active skin lesion(s) of any morphological appearance (including but not limited to livedo, induration, ulceration, etc.) and tissue histology review consistent with calciphylaxis diagnosis. Histological features consistent with calciphylaxis will include soft tissue calcification, microthrombosis, and/or fibrointimal hyperplasia of dermal arterioles
- •Acute pain associated with calciphylaxis lesions pain intensity score of ≥ 5 at initial screening on the modified BPI/SF scale
- •Women of childbearing potential must have a pregnancy test (urine or serum [if anuric]) at screening and not be pregnant and willing to use an acceptable method of contraception for the entire duration of the study (3 weeks)
排除标准
- •Peritoneal dialysis patients
- •Current congestive heart failure exacerbation
- •Baseline abnormalities related to QT prolongation (corrected QT interval > 470 ms), hypocalcemia (serum albumin-corrected calcium < 8 mg/dL ), metabolic acidosis (serum bicarbonate < 18 mmol/L, hypotension (resting systolic blood pressure while seated < 80), or interdialytic weight gain ≥ 4.0 kg
- •History of ventricular arrhythmias including ventricular fibrillation or ventricular tachycardia associated with shortness of breath, dizziness, hypotension, or syncope
- •Any prior (within the past 30 days) or current intravenous Sodium Thiosulfate Injection treatment
- •Other investigational agent (drug, biologic, or device) study within the past 30 days and/or for the duration of the trial
- •Pregnant or lactating women
- •History of allergy to sulfites, thiosulfate, or any component in Sodium Thiosulfate Injection (sulfa allergy is not an exclusion criterion)
- •Significant other acute or chronic concomitant diseases (including but not limited to hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 3 months
- •Other serious concurrent or recent medical or psychiatric condition which, in the opinion of the Investigator, makes the patient unsuitable for participation in this study
- •Ongoing application of dialysate admixed with iron salt e.g. ferric pyrophosphate during the entire trial period (patients who are on dialysate admixed with iron salt at screening are eligible if dialysate admixed with iron salt can be substituted with non-iron based dialysate and patients can be maintained on non-iron based dialysate therapy for the entire duration of trial period)
- •Recent (within 1 week) history of surgical parathyroidectomy or scheduled for surgical parathyroidectomy during the course of the study
- •History of opioid addiction
研究组 & 干预措施
Sodium Thiosulfate
Experimental
Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
干预措施: Sodium Thiosulfate (Drug)
Placebo-Normal Saline
Placebo Comparator
0.9% sodium chloride injection, USP (normal saline)
干预措施: Placebo-Normal Saline (Drug)
结局指标
主要结局
Number of patients with 30% improvement in pain severity
时间窗: randomization to 3 weeks
To compare the effects of treatment with intravenous Sodium Thiosulfate Injection vs. placebo for the proportion of patients (responders) who achieve a ≥ 30% reduction based upon pain intensity score (modified BPI/SF).
次要结局
- Secondary Endpoint-b: Occurence of surgical debridement of skin lesions and/or amputation.(during week 3)
- Secondary Endpoint-d: Time to achieve ≥ 30% improvement in pain severity(randomization to 3 weeks)
- Secondary Endpoint-a: Number of patients with stabilization or improvement in calciphylaxis skin lesions.(randomization to 3 weeks)
- Secondary Endpoint-c: Occurrence of surgical debridement of skin lesions and/or amputation.(randomization to 3 weeks)
研究者
研究点 (20)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to evaluate the use of sodium thiosulfate for the treatment of patients with calciphylaxis (accumulation of calcium in small blood vessels of the fat and skin tissues)EUCTR2018-002751-15-GBHope Pharmaceuticals Ltd111
已完成
3 期
MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00854035Ono Pharmaceutical Co. Ltd266
进行中（未招募）
3 期
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)Social Anxiety DisorderNCT06358651VistaGen Therapeutics, Inc.238
进行中（未招募）
3 期
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)Social Anxiety Disorder (SAD)NCT06615557VistaGen Therapeutics, Inc.238
已完成
3 期
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)Breast CancerNCT01120184Hoffmann-La Roche1,095